Marie-Hélène Auclair

Dr. Marie-Hélène Auclair

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2023 in Current Oncology
Verified
Journal Article
Open access
PDF file
KWKarla Willows
Karla Willows
ASAmanda Selk
Amanda Selk
MAMarie-Hélène Auclair
Marie-Hélène Auclair
BJBrent Jim
Brent Jim
NJNaana Jumah
Naana Jumah
JBJames Bentley
James Bentley
This guideline provides evidence-based guidance on the risk-based management of cervical dysplasia in the colposcopy setting in the context of primary HPV-based screening and HPV testing in colposcopy. Colposcopy management of special populations is also discussed. The guideline was developed by a working group in collaboration with the Gynecologic Oncology Society of Canada (GOC), Society of Colposcopists of Canada (SCC) and the Canadian Partnership Against Cancer (CPAC). The literature informing these guidelines was obtained through a systematic review of the relevant literature via a multi-step search process led by information specialists. The literature was reviewed up to June 2021 with manual searches of relevant national guidelines and more recent publications. Quality of the evidence and strength of recommendations was assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework. The intended users of this guideline include gynecologists, colposcopists, screening programs and healthcare facilities. Implementation of the recommendations is intended to promote equitable and standardized care for all people undergoing colposcopy in Canada. The risk-based approach aims to improve personalized care and reduce over-/under-treatment in colposcopy.

1 October 2008 in Interactive CardioVascular and Thoracic Surgery
Verified
Journal Article
Open access
PDF file
RARony Atoui
Rony Atoui
VEVidal Essebag
Vidal Essebag
VWValerie Wu
Valerie Wu
YGYin Ge
Yin Ge
MAMarie-Hélène Auclair
Marie-Hélène Auclair
DSDominique Shum-Tim
Dominique Shum-Tim
Transvenous coronary sinus lead placement is currently the standard approach for left ventricular pacing. The aim of this study is to assess whether a mini-thoracotomy approach would be feasible and safe when used for cases in which transvenous procedures were ineffective or judged unlikely to succeed. Biventricular pacing was performed in 138 consecutive patients with 47 patients undergoing a mini-thoracotomy procedure. NYHA status, quality of life, electrical and echocardiographic data were assessed in the two groups over a follow-up period of 17.6±4.2 weeks. There was no significant difference in the preoperative characteristics in both groups other than a greater prevalence of renal failure and previous cardiac surgery among the surgical patients. The mean procedure time was significantly longer in the transvenous group. No significant differences were noted in the immediate or long-term pacing parameters. Two mortalities were observed in the surgical group >2 weeks following the procedure. During the follow-up period, we noted a comparable improvement in the echocardiographic parameters, QRS duration and NYHA status with both approaches. Our results suggest that even when performed on high-risk patients, epicardial lead placement through a mini-thoracotomy is beneficial and feasible as a ‘rescue’ procedure after a failed transvenous approach.

1 September 2021 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
ABAlexandre Brind'Amour
Alexandre Brind'Amour
VPVera Pravong
Vera Pravong
Lucas SiderisLucas Sideris
Lucas Sideris
PDPierre Dubé
Pierre Dubé
LGLara De Guerke
Lara De Guerke
JTJean-François Tremblay
Jean-François Tremblay

29 November 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
MKMaher Al Khaldi
Maher Al Khaldi
MFMassine Fellouah
Massine Fellouah
PDPierre Drolet
Pierre Drolet
JCJulien Côté
Julien Côté
BTBertrand Trilling
Bertrand Trilling
Lucas SiderisLucas Sideris
Lucas Sideris
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is a treatment option for peritoneal metastases (PM) but is associated with significant postoperative morbidity. The aim of this study was to determine the prognostic value of computed tomographic (CT)-measured sarcopenia on postoperative outcomes and survival in patients undergoing CRS-HIPEC for PM from various origins. A retrospective cohort study was conducted between 2012 and 2020. Three-hundred and twelve patients (mean age 57.6 ± 10.3, 34.3% male) were included, of which 88 (28.2%) were sarcopenic. PM from a colorectal origin was the most common in both groups. The proportion of major postoperative complications (Clavien-Dindo ≥ III) was not higher in the sarcopenic group (15.9% in sarcopenic patients vs. 23.2% in nonsarcopenic patients, p = 0.17). The mean Comprehensive Complication Index scores, HIPEC-related toxicities, length of hospital stay, and duration of parenteral nutrition were comparable regardless of sarcopenia status. In the multivariate logistic regression analysis of severe complications, only peritoneal carcinomatosis index reached statistical significance (OR, 1.05; 95% CI, 1.01 to 1.08, p = 0.007). Sarcopenia did not impact origin-specific overall survival on Cox regression analysis. Sarcopenia was not associated with worse rates of postoperative severe complications or worse survival rates. Future prospective studies are required before considering sarcopenia as part of preoperative risk assessment.

4 June 2026 in Journal of Obstetrics and Gynaecology Canada
Verified
Journal Article
Open access
ADAnne-Julie Dubé
Anne-Julie Dubé
SBSophie Baril
Sophie Baril
CLCharlotte Lemieux-Bourque
Charlotte Lemieux-Bourque
SPSabrina Piedimonte
Sabrina Piedimonte
SFSuzanne Fortin
Suzanne Fortin
MAMarie-Hélène Auclair
Marie-Hélène Auclair
Endometrial intraepithelial neoplasia (EIN) carries a notable risk of concurrent endometrial carcinoma; however, the role of routine lymphadenectomy remains uncertain. This study evaluated the role, safety, and outcomes of sentinel lymph node dissection (SLNd) in patients with preoperative EIN, aiming to identify those with occult carcinoma or nodal metastases who may benefit from adjuvant therapy. This retrospective cohort study included patients with EIN who underwent hysterectomy with or without SLNd at 2 university hospitals between February 2017 and December 2021. The primary outcome was the rate of lymph node metastasis in the SLNd group; secondary outcomes included SLN mapping success, detection of carcinoma on final pathology, SLNd-associated morbidity, and adjuvant treatment requirements. Among 107 patients, 86 (80.4%) underwent SLNd or complete lymphadenectomy, and 21 (19.6%) had hysterectomy alone. SLN mapping was successful in 90.7% of patients, with bilateral mapping in 69.8%. Endometrial carcinoma was identified in 48% of SLNd patients versus 15% of those undergoing hysterectomy alone. Nodal metastasis occurred in 1 of 78 patients (1.2%), consisting solely of isolated tumour cells. No complications were directly attributable to SLNd no significant differences in hospital length stay, blood loss, operative time, or overall complication rates. Adjuvant therapy was required in 7 patients (8.1%) undergoing SLND. In this cohort, SLNd demonstrated a favourable safety profile and high detection rates; however, the overall incidence of nodal metastasis was low (1.2%). These findings support a selective rather than routine lymph node evaluation strategy in this population. Furthermore, identification of positive SLNs did not lead to changes in clinical management, indicating a limited impact on therapeutic decision-making for patients with otherwise low-risk disease.

1 December 2023 in Current Oncology
Verified
Journal Article
Open access
PDF file
CBClaudele Brault
Claudele Brault
ABAlexandre Brind'Amour
Alexandre Brind'Amour
LGLara de Guerke
Lara de Guerke
MAMarie-Hélène Auclair
Marie-Hélène Auclair
Lucas SiderisLucas Sideris
Lucas Sideris
SFSuzanne Fortin
Suzanne Fortin
Combining interval cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) improves survival in advanced epithelial ovarian carcinoma (EOC). Although limited, growing evidence regarding carboplatin-based HIPEC highlights its potential. This retrospective study included all patients with advanced primary high-grade serous ovarian cancer who underwent interval CRS combined with carboplatin-based HIPEC at our Canadian tertiary care center between 2014 and 2020. We identified 40 patients with a median age of 61 years. The median peritoneal cancer index was 13 and complete cytoreduction was achieved in 38 patients (95%). Median hospital stay was 13 days and there were four admissions to the intensive care unit (10%) and six readmissions (15%). Severe adverse events occurred in eight patients (20%) and there was no perioperative death. Recurrence was seen in 33 patients (82%) with a median DFS of 18.0 months and a median overall survival of 36.4 months. Multivariate analyses showed that age, peritoneal cancer index, completeness of cytoreduction, occurrence of severe complications, and bowel resection did not significantly impact DFS or OS in our cohort. Interval CRS combined with carboplatin-based HIPEC for advanced primary EOC is associated with acceptable morbidity and oncological outcomes. Larger studies are required to determine the long-term outcomes.